Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S has completed its share buy-back program, repurchasing 342,130 shares for a total of 615,105,001 DKK to meet commitments under its Restricted Stock Unit program. The program, launched on February 17, 2026, finished on March 13, 2026, earlier than expected.
From March 9 to March 13, 2026, Genmab bought 93,130 shares, including 25,130 shares on March 13 at an average price of 1,717.39 DKK. After these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.
Genmab A/S provides an update on its share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to cover Restricted Stock Unit commitments. From March 2 to March 6, 2026, the company repurchased 101,000 shares for a total of DKK 180,733,150, bringing total repurchases under the program to 249,000 shares at a total value of DKK 452,588,620. Genmab corrects a previously reported “Accumulated through last announcement” figure, which should have been 63,000 shares, resulting in a corrected accumulated figure of 148,000 shares. After these transactions, Genmab holds 2,766,533 treasury shares, equal to 4.31% of its total share capital and voting rights.
Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.
Genmab A/S provides an update on its ongoing share buy-back program, which was initiated to repurchase up to 342,130 shares for a maximum of DKK 725 million to honor commitments under its Restricted Stock Unit program.
From February 23 to 27, 2026, Genmab repurchased 18,000, 12,000, 15,000, 20,000 and 20,000 shares on successive trading days, at average prices between DKK 1,825.23 and DKK 1,856.49, for total consideration of DKK 156,630,920 during this period and DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 treasury shares, equal to 4.30% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.
Genmab A/S is making a small share capital increase after employees exercised warrants, issuing 12,313 new shares. The new shares were subscribed for cash at various prices between DKK 1,147.50 and DKK 1,615.00 per share, generating approximately DKK 17.1 million in proceeds for the company.
The new shares equal about 0.02% of Genmab’s existing share capital and carry the same rights as existing ordinary shares, including voting and dividend rights from subscription. After this increase, the total nominal share capital is DKK 64,250,721, corresponding to 64,250,721 shares and votes, and the new shares are expected to be listed on Nasdaq Copenhagen following registration.
Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.
From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.
Genmab A/S is convening its Annual General Meeting on March 19, 2026 in Copenhagen and outlining key proposals for shareholder approval. Shareholders will be asked to adopt the audited 2025 Annual Report, grant discharge to the Board and Executive Management, and carry forward the profit of USD 963 million to retained earnings rather than paying a dividend.
The agenda includes an advisory vote on the 2025 Compensation Report, re-election of six directors, and re-appointment of Deloitte as auditor, including a limited assurance engagement on sustainability statements. Board and committee fees for 2026 are proposed to remain at 2025 levels, with a base fee of DKK 600,000 and specified supplements for chair, deputy chair and committee roles, plus restricted stock units under the remuneration policy.
Genmab’s Board also proposes a share capital reduction by nominally DKK 1,900,000 through cancellation of 1,900,000 treasury shares that were repurchased for a total of DKK 2,473,734,807.58, at an average price of DKK 1,301.97 per share. Following this, the Articles of Association would be amended to reflect the reduced share capital, which is currently DKK 64,238,408 divided into shares of DKK 1 each, with one vote per share.
Genmab A/S is launching a share buy-back program of up to 342,130 shares with a maximum total value of 725 million DKK. The program is designed to meet obligations under the company’s Restricted Stock Unit program and will run from February 18, 2026, and is expected to end no later than March 31, 2026, unless suspended or terminated.
Genmab has given a non-discretionary mandate to Danske Bank, which will independently execute purchases on Nasdaq Copenhagen and multilateral trading facilities under EU market abuse and Safe Harbour rules. As of February 17, 2026, Genmab holds 2,615,851 treasury shares, equal to 4.07% of its share capital.